2026-06-14T03:53:08Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/179812024-09-21T21:23:11Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Mena-Vázquez, Natalia author Fernández-Nebro, Antonio author Pego-Reigosa, José María author Galindo, María author Melissa-Anzola, Ana author Uriarte-Isacelay, Esther author Olivé-Marqués, Alejandro author Aurrecoechea, Elena author Freire, Mercedes author Tomero, Eva author García-Villanueva, María Jesús author Stoye, Claudia author Salas-Heredia, Esteban author Bernal-Vidal, Jose Antonio author Salgado, Eva author Blanco, Ricardo author Javier Novoa, Francisco author Ibáñez-Barcelo, Mónica author Torrente-Segarra, Vicente author Narvaez, Javier author Calvet, Joan author Moriano Morales, Clara author Ramon Vazquez-Rodriguez, Tomas author Garcia de la Peña, Paloma author Bohórquez, Cristina author Andreu-Sánchez, José Luis author Cobo-Ibañez, Tatiana author Bonilla, Gema author Lozano-Rivas, Nuria author Montilla, Carlos author Toyos, Francisco Javier author De la Fuente, Jose Luis Marenco author Expósito, Lorena author Ruiz-Lucea, María Esther author Vals, Elia author Manero-Ruiz, Javier author Bernal-Vidal, Jose A author Rua-Figueroa, Iñigo author 2020 This article estimates the frequency of polyautoimmunity and associated factors in a large retrospective cohort of patients with SLE. RELESSER (Spanish Society of Rheumatology Lupus Registry) is a nationwide multicentre, hospital-based registry of SLE patients. This is a cross-sectional study. The main variable was polyautoimmunity, which was defined as the co-occurrence of SLE and another autoimmune disease, such as autoimmune thyroiditis, RA, scleroderma, inflammatory myopathy and MCTD. We also recorded the presence of multiple autoimmune syndrome, secondary SS, secondary APS and a family history of autoimmune disease. Multiple logistic regression analysis was performed to investigate possible risk factors for polyautoimmunity. Of the 3679 patients who fulfilled the criteria for SLE, 502 (13.6%) had polyautoimmunity. The most frequent types were autoimmune thyroiditis (7.9%), other systemic autoimmune diseases (6.2%), secondary SS (14.1%) and secondary APS (13.7%). Multiple autoimmune syndrome accounted for 10.2% of all cases of polyautoimmunity. A family history was recorded in 11.8%. According to the multivariate analysis, the factors associated with polyautoimmunity were female sex [odds ratio (95% CI), 1.72 (1.07, 2.72)], RP [1.63 (1.29, 2.05)], interstitial lung disease [3.35 (1.84, 6.01)], Jaccoud arthropathy [1.92 (1.40, 2.63)], anti-Ro/SSA and/or anti-La/SSB autoantibodies [2.03 (1.55, 2.67)], anti-RNP antibodies [1.48 (1.16, 1.90)], MTX [1.67 (1.26, 2.18)] and antimalarial drugs [0.50 (0.38, 0.67)]. Patients with SLE frequently present polyautoimmunity. We observed clinical and analytical characteristics associated with polyautoimmunity. Our finding that antimalarial drugs protected against polyautoimmunity should be verified in future studies. 10.1093/rheumatology/kez562 1462-0332 Rheumatology (Oxford, England) http://hdl.handle.net/10668/14796 31808534 http://hdl.handle.net/20.500.12105/17981 Multiple autoimmune syndrome Polyautoimmunity Systemic lupus erythematosus Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry.